Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study

Table 2 Administration schedule

Date	Route	WJ-MSCs
Round 1
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)
Round 2 (2nd wk)
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)
Round 3 (1st month)
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)
Round 4 (2nd month)
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)
Round 5 (3rd month)
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)
Round 6 (4th month)
	I.t.	1 × 106/kg (3 mL in total)
	I.v.	1 × 106/kg (30 mL in total)
	I.m.	1 × 106/kg (20 mL in total)

I.t.: Intrathecal; I.v.: Intravenous; I.m.: Intramuscular; WJ-MSCs: Wharton’s Jelly-derived mesenchymal stem cells.